Pharmacy

Sanofi-aventis has announced that it has received   marketing   authorization; from the European Commission for Jevtana'® (cabazitaxel) in combination with prednisone " prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen.

sanofi-aventis has also signed a new agreement with the World Health Organization (WHO) to donate $25 million to fight neglected tropical diseases, extending its decade-long partnership with the WHO for another five years. The agreement was signed by Christopher A. Viehbacher, Chief Executive Officer, sanofi- aventis, and Dr Margaret Chan, WHO Director-General, WHO headquarters, Geneva, Switzerland.

Since the partnership in 2001, over 150,000 patients have been treated for sleeping sickness, a fatal disease if left untreated. The number of patients treated for sleeping sickness has dropped by over 60 per cent.